©The Author(s) 2026.
World J Gastrointest Oncol. Feb 15, 2026; 18(2): 114161
Published online Feb 15, 2026. doi: 10.4251/wjgo.v18.i2.114161
Published online Feb 15, 2026. doi: 10.4251/wjgo.v18.i2.114161
Figure 1 Identification of the gastric intestinal metaplasia mouse model and the effects of taurine intervention.
A: Hematoxylin and eosin staining of the mouse gastric mucosa (n = 6); B: Alcian blue-periodic acid Schiff staining of the mouse gastric mucosa (n = 6); C: Relative expression levels of gastric intestinal metaplasia-related genes detected by quantitative PCR (qPCR; n = 6); D: Relative expression level of MUC5AC detected by qPCR (n = 6). aP < 0.05 vs wild-type (WT); bP < 0.01 vs WT; cP < 0.05 vs Atp4a-/-; dP < 0.01 vs Atp4a-/-.
- Citation: Liu K, Zhang X, Li FZ, Zheng PY, Mi Y. Taurine suppresses gastric intestinal metaplasia in patient-derived organoids and Atp4a-/- mice. World J Gastrointest Oncol 2026; 18(2): 114161
- URL: https://www.wjgnet.com/1948-5204/full/v18/i2/114161.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v18.i2.114161